■皮肤鳞状细胞癌(SCC)是一种常见的皮肤癌,具有显著的发病率和死亡率,特别是在高级阶段。由于对治疗耐受性和潜在不良反应的担忧,高龄患者转移性皮肤SCC的治疗选择有限。
■我们报告了一例90岁女性转移性皮肤SCC患者接受cemiplimab治疗,抗程序性细胞死亡蛋白1(PD-1)的单克隆抗体(m-Ab),结合放疗。患者接受cemiplimab治疗的时间有限,在此期间,她表现出显著的临床改善,没有严重的不良事件。放射疗法作为局部治疗进行,目的是增强免疫疗法的功效。
■该病例突出了cemiplimab在患有转移性皮肤SCC的高龄患者中的可行性和有效性。尽管人们普遍担心在这个年龄段使用免疫疗法,我们的病人对cemiplimab耐受良好,与放疗的结合被证明是有益的。这表明,即使在非常年长的患者中,短期使用cemiplimab,结合局部治疗,如放疗,可以是一个可行的和成功的治疗方法。
■Cemiplimab,即使与放射治疗相结合,可以有效和安全地给予患有转移性皮肤SCC的高龄患者。这个案例支持免疫疗法的考虑,即使是有限的时间,作为老年患者晚期皮肤SCC管理的一种实用选择,扩大该人群的潜在治疗策略。
UNASSIGNED: Cutaneous squamous cell carcinoma (SCC) is a common skin cancer with significant morbidity and mortality, particularly in advanced stages. Treatment options for metastatic cutaneous SCC in very elderly patients are limited due to concerns about treatment tolerability and potential adverse effects.
UNASSIGNED: We report the case of a 90-year-old female patient with metastatic cutaneous SCC who was treated with cemiplimab, a monoclonal antibody (m-Ab) against programmed cell death protein 1 (PD-1), in combination with radiotherapy. The patient received cemiplimab for a limited period, during which time she demonstrated significant clinical improvement without severe adverse events. Radiotherapy was performed as a locoregional treatment with the aim to enhance immunotherapy efficacy.
UNASSIGNED: This case highlights the feasibility and effectiveness of cemiplimab in very elderly patients with metastatic cutaneous SCC. Despite the common apprehensions regarding the use of immunotherapy in this age group, our patient tolerated cemiplimab well, and the combination with radiotherapy proved beneficial. This suggests that even in very elderly patients, short-term use of cemiplimab, in conjunction with locoregional treatments such as radiotherapy, can be a viable and successful therapeutic approach.
UNASSIGNED: Cemiplimab, even in combination with radiotherapy, can be effectively and safely administered to very elderly patients with metastatic cutaneous SCC. This case supports the consideration of immunotherapy, even for a limited duration, as a practical option in the management of advanced cutaneous SCC in elderly patients, expanding the potential treatment strategies for this population.